No Data
Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 38.81 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 13, $NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)(NAMSW.US)$、$NewAmsterdam Pharma(NAMS.US)$ Insider NAP PoolCo B.V. intends to sell 1.55 million shares of its common
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Clinical Trials and Innovative Lipid-Lowering Therapies
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35